Ionis Pharmaceuticals, Inc.
IONS
주식 순위
#2665
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
주가
$42.95
마지막 동기화: 2026-10-16
시가총액
$7.14B
변동 (1일)
-2.65%
변동 (1년)
-41.23%
국가
US
거래 Ionis Pharmaceuticals, Inc. (IONS)
카테고리
Healthcare
Ionis Pharmaceuticals, Inc. (IONS)의 영업이익률
October 2026 기준 영업이익률 TTM: -68.09%
Ionis Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -68.09%입니다. 2023년 말 기준 영업이익률은 -44.91%였습니다.
Ionis Pharmaceuticals, Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | -68.09% | 1.07% |
| 2024 | -67.37% | 50.01% |
| 2023 | -44.91% | -35.86% |
| 2022 | -70.02% | 1,777.21% |
| 2021 | -3.73% | -84.19% |
| 2020 | -23.59% | -172.38% |
| 2019 | 32.59% | -418.57% |
| 2018 | -10.23% | -311.80% |
| 2017 | 4.83% | -136.15% |
| 2016 | -13.36% | -49.96% |
| 2015 | -26.70% | 19.78% |
| 2014 | -22.29% | -36.46% |
| 2013 | -35.08% | -48.06% |
| 2012 | -67.54% | -5.88% |
| 2011 | -71.76% | 60.97% |
| 2010 | -44.58% | 96.82% |
| 2009 | -22.65% | 85.96% |
| 2008 | -12.18% | -78.23% |
| 2007 | -55.94% | -79.85% |
| 2006 | -277.67% | 94.88% |
| 2005 | -142.48% | -48.47% |
| 2004 | -276.49% | 75.00% |
| 2003 | -157.99% | 149.31% |
| 2002 | -63.37% | -26.77% |
| 2001 | -86.54% | 11.21% |
| 2000 | -77.82% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -100.57% |
US
|
|
| -149.01% | -97.81% |
US
|
|
| 25.57% | -100.38% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.42% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.